About the Company
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs (see the Products section below).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SRPT News
This Is What Whales Are Betting On Sarepta Therapeutics
High-rolling investors have positioned themselves bullish on Sarepta Therapeutics SRPT, and it's important for retail traders to take note. \\This activity came to our attention to ...
Sarepta Therapeutics gets grant for antisense oligomers for treating dystrophic epidermolysis bullosa
Discover how Sarepta Therapeutics' patented antisense oligomers target collagen mRNA to treat dystrophic epidermolysis bullosa and related disorders.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.47, expectations were $-0.03. Sarepta Therapeutics ...
Sarepta Therapeutics Inc SRPT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Sarepta Therapeutics Inc’s (SRPT) Stock: A -1.43% Simple Moving Average for the Past 20 Days
The stock of Sarepta Therapeutics Inc (SRPT) has gone down by -1.07% for the week, with a 2.01% rise in the past month and a 4.41% rise in the past quarter. The volatility ratio for the week is 2.28%, ...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation ...
Sarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for Elevidys
Sarepta Therapeutics (SRPT) Company Description: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for ...
Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock increases 3.6% this past week
But if you pick the right individual stocks, you could make more than that. For example, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shareholders have seen the share price rise 70% over three years ...
Sarepta Therapeutics Inc
Semiconductor ETFs can help investors tap into tailwinds such as demand from artificial intelligence, government grants and a re-shoring movement.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were ...
Sarepta Therapeutics Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...